OKYO Pharma says cash position funds completion of NEPTUNE Phase 3 urcosimod trial
OKYO•NEPTUNE trial planned for H2 2026
NEPTUNE, an FDA-agreed global Phase 3 pivotal study of urcosimod in neuropathic corneal pain, is planned to start in H2 2026.
The trial targets about 111 patients in the US and Europe, randomized 2:1 to 0.05% urcosimod or placebo in a single-dose regimen.
Cash position and recent offering support Phase 3 program
OKYO Pharma filed its annual report for the fiscal year ended March 31, 2026, citing a strengthened cash position to fund a Phase 3 program.
February 2026 public offering raised about $22 million in gross proceeds, including overallotment, boosting liquidity.
Cash and cash equivalents totaled about $20.6 million at March 31, 2026, with funding expected through completion of the NEPTUNE Phase 3 trial.
